After the spin-off of Alcon was approved by Novartis shareholders with 99.8 percent of the votes at the general annual meeting on Feb. 28, the pharmaceutical giant announced that it had received all necessary authorizations to move ahead. The transaction is now expected to be completed on April 9, 2019, ...
Buying a membership today will give you:
To continue reading this article register now.